Chiome Bioscience Inc. announced that it had received notification of the achievement of a miletone from ADC Therapeutics SA, pursuant to the License Agreement of September 27, 2017 in association with the progress in the development of ADCT-701. Under the License Agreement Chiome granted ADCT the worldwide, exclusive, sub-licensable right to LIV-1205 for the development, manufacture and commercialization in Antibody Drug Conjugete (ADC) fields. ADCT has conducted preclinical studies towards clinical development. This milestone was triggered by successful completion of toxicology study enabling an IND filing, and Chiome will receive a milestone payment based on the agreement. This milestone payment will be recorded as operating revenue in the fourth quarter, and it has little impact on the financial performance in the fiscal period ending December 31, 2019.